scholarly journals Population-Level Herd Protection of Males From a Female Human Papillomavirus Vaccination Program: Evidence from Australian Serosurveillance

2017 ◽  
Vol 65 (5) ◽  
pp. 827-832 ◽  
Author(s):  
Alexis J Pillsbury ◽  
Helen E Quinn ◽  
TaNisha D Evans ◽  
Peter B McIntyre ◽  
Julia M L Brotherton
Sexual Health ◽  
2016 ◽  
Vol 13 (5) ◽  
pp. 489 ◽  
Author(s):  
Eric P. F. Chow ◽  
Christopher K. Fairley

Australian-born women aged ≤32 years were eligible for the free female human papillomavirus (HPV) vaccination program introduced in 2007. A total of 1165 heterosexual couples attending the Melbourne Sexual Health Centre between 2011 and 2014 were included in this analysis. Findings showed the odds of having penile warts was 0.52-fold lower among men who had a female partner aged ≤32 years compared with men who had a female partners aged >32 years. This suggests men would have received herd protection from their female partners and hence they are at lower risk of acquiring genital warts.


Sexual Health ◽  
2016 ◽  
Vol 13 (4) ◽  
pp. 395 ◽  
Author(s):  
Eric P. F. Chow ◽  
Christopher K. Fairley

The aim was to investigate the assortative sexual mixing by country of birth among heterosexuals in Australia. An analysis of 1060 heterosexual couples who attended the Melbourne Sexual Health Centre between 2011 and 2014 was conducted. Of the 1060 couples, 27% (n = 281) were both Australian-born men and women, and 42% (n = 445) were both overseas-born. Of the 171 couples with women aged ≤21 years, 41% (n = 70) were both born in Australia and 33% (n = 56) were both born overseas. A strong assortative mixing pattern by country of birth was observed among all 1060 couples (r = 0.361; 95% CI: 0.320–0.403), and among 171 couples with women aged ≤21 years (r = 0.481; 95% CI: 0.379–0.584).


2016 ◽  
Vol 22 (10) ◽  
pp. 1732-1740 ◽  
Author(s):  
David Mesher ◽  
Kate Soldan ◽  
Matti Lehtinen ◽  
Simon Beddows ◽  
Marc Brisson ◽  
...  

2019 ◽  
Vol 8 ◽  
pp. 100189 ◽  
Author(s):  
Sapna Kaul ◽  
Thuy Quynh N. Do ◽  
Enshuo Hsu ◽  
Kathleen M. Schmeler ◽  
Jane R. Montealegre ◽  
...  

2016 ◽  
Vol 215 (3) ◽  
pp. 318.e1-318.e9 ◽  
Author(s):  
Abbey B. Berenson ◽  
Mahbubur Rahman ◽  
Jacqueline M. Hirth ◽  
Richard E. Rupp ◽  
Kwabena O. Sarpong

Sexual Health ◽  
2015 ◽  
Vol 12 (6) ◽  
pp. 520 ◽  
Author(s):  
Luke B. Connelly ◽  
Ha N. D. Le

Background Human papillomavirus (HPV) vaccines and their widespread adoption have the potential to relieve a large part of the burden of cervical cancer morbidity and mortality, particularly in countries that have low screening rates or, like Japan, lack a cohesive universal screening program. An economic evaluation was conducted to assess the cost-effectiveness of introducing a bivalent HPV vaccination program in Japan from a healthcare perspective. Methods: A Markov model of the natural history of HPV infection that incorporates both vaccination and screening was developed for Japan. The modelled intervention, a bivalent HPV vaccine with a 100% lifetime vaccine efficacy and 80% vaccine coverage, given to a cohort of 12-year-old Japanese girls in conjunction with the current screening program, was compared with screening alone in terms of costs and effectiveness. A discount rate of 5% was applied to both costs and utilities where relevant. Results: Vaccination alongside screening compared with screening alone is associated with an incremental cost-effectiveness ratio (ICER) of US$20 315 per quality-adjusted-life-year gained if 80% coverage is assumed. The ICER at 5% coverage with the vaccine plus screening, compared with screening alone, is US$1158. Conclusion: The cost-effectiveness results suggest that the addition of a HPV vaccination program to Japan’s cervical cancer screening program is highly likely to prove a cost-effective way to reduce the burden of cervical cancer, precancerous lesions and HPV16/18-related diseases.


Sign in / Sign up

Export Citation Format

Share Document